Document 2827
 DOCN  M94A2827
 TI    Binational experience in the treatment of AIDS with a low molecular
       weight natural carbohydrate (ECA-10-142), as stimulant of the immunology
       system.
 DT    9412
 AU    Cevallos Arellano E; Ardila Ardila H; Oncology Clinic, Metropolitan
       Hospital, Quito, Ecuador.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):216 (abstract no. PB0294). Unique
       Identifier : AIDSLINE ICA10/94369748
 AB    OBJECTIVES: to evaluate the stimulant properties of the immunological
       system of the (ECA-10-142) a low weight natural origin carbohydrate, in
       70 IV CDC stage AIDS patients METHODS: 70 patients with AIDS confirmed
       diagnosis were selected, 30 Colombians and 40 Ecuadorians, for oral
       treatment with (ECA-10-142). In a period of 9 months. In the evaluations
       were considered clinical symptoms and signs, total percentage of
       lymphocytes, CD4 and CD8 cells percentage and its relationships. In
       vitro studies demonstrated also that this carbohydrate stimulates the
       immunological system in the AIDS patients. RESULTS: the obtained results
       in the 9 months demonstrated a clinical improvement as to signs and
       symptoms in 64 (91.4%) patients, immunological recuperation of CD4
       levels in 66 (94.3%) patients, clinical and immunological improvement
       were presented in 64 (91.4%) patients, 4 (5.7%) patients died due to
       their advanced state of the sickness. They only received treatment
       during one month, and had their CD4 levels under 100. DISCUSSION AND
       CONCLUSIONS: the (ECA 10-142) has demonstrated to be a useful vitro and
       in vivo stimulated of the immunological system as inhibits the formation
       of syncytial masses in a 59% and is effective as the clinical and
       immunological improvement of AIDS patients. Kinetics studies are
       required and observations in a longer time in order to conclude it's
       immunostimulating activity in AIDS patients.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY  Adjuvants,
       Immunologic/PHARMACOLOGY/*THERAPEUTIC USE  Biological
       Products/*THERAPEUTIC USE  Carbohydrates/PHARMACOLOGY/*THERAPEUTIC USE
       Colombia  Cytopathogenic Effect, Viral/DRUG EFFECTS  Ecuador  Human
       Treatment Outcome  CLINICAL TRIAL  MEETING ABSTRACT  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).